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Background: To limit selective and incomplete publication of the results of clinical trials, registries including
ClinicalTrials.gov were introduced. The ClinicalTrials.gov registry added a results database in 2008 to enable
researchers to post the results of their trials as stipulated by the Food and Drug Administration Amendment
Act of 2007. This study aimed to determine the direction and magnitude of any change in publication proportions
of registered breast cancer trials that occurred since the inception of the ClinicalTrials.gov results database.
Methods: A cross-sectional study design was employed using ClinicalTrials.gov, a publicly available registry/results
database as the primary data source. Registry contents under the subcategories ‘Breast Neoplasms’ and ‘Breast
Neoplasms, Male’ were downloaded on 1 August 2015. A literature search for included trials was afterwards
conducted using MEDLINE and DISCOVER databases to determine publication status of the registered breast
cancer trials.
Results: Nearly half (168/340) of the listed trials had been published, with a median time to publication of 24 months
(Q1 = 14 months, Q3 = 42 months). Only 86 trials were published within 24 months of completion. There was no
significant increase in publication proportions of trials that were completed before the introduction of the results
database compared to those completed after (OR = 1.00, 95 % CI = .61 to 1.63; adjusted OR = 0.84, 95 % CI = .51 to
1.39). Characteristics associated with publication included trial type (observational versus interventional adjusted
OR = .28, 95 % CI = .10 to .74) and completion/termination status (terminated versus completed adjusted OR = .22,
95 % CI = .09 to .51).
Conclusions: Less than a half of breast cancer trials registered in ClinicalTrials.gov are published in peer-reviewed
journals.
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“Full and transparent reporting of trials is crucial to en-
sure that decisions about health care are based on the best
available evidence.” [1]. Selective, incomplete or delayed
reporting of trial results (for instance, due to their statis-
tical significance, effect size or direction) distorts the avail-
able evidence, compromises systematic reviews, renders
evidence-based decisions inaccurate, wastes resources and* Correspondence: innocentgerald@yahoo.co.uk
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(http://creativecommons.org/publicdomain/zeis unethical [2–10]. There is evidence of selective, in-
complete and delayed reporting across several if not all
fields, including cancer, cardiovascular disease and
neurological disorders [11, 12]; pain [13]; surgery [14];
arthritis [15]; oral health [16]; eczema [17]; and acu-
puncture [18]. Registration of trials at their inception
and appropriate follow-up was proposed to enable the
tracking of protocol changes as well as improve re-
search transparency, accountability and integrity [8].
Examples of trial databases/registries established to ac-
complish these objectives are ClinicalTrials.gov and thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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by the US National Institute of Health (NIH) in 2000
and the European Medicines Agency (EMA) in 2004
respectively [19, 20].
Despite the establishment of these registries, the ultim-
ate aim of trial registration (full and transparent reporting)
has not been achieved. Empirical evidence demonstrates a
continued low compliance to the required reporting stan-
dards [8]. For instance, Ross and colleagues [21] reported
that less than a half of trials funded by the National Insti-
tute of Health (n = 635) were published within 30 months
of being completed. In addition to the incomplete report-
ing, there was a lack of transparency with trial outcomes
being changed to favour positive or statistically significant
findings [22]. These results were consistent to those re-
ported before trial registries were established [23–27].
Earlier studies have reported that investigators are
less likely to submit negative or null findings [6, 24].
Originally, trial registries/databases did not mandate
the submission of trial findings; however, it was hoped
that an additional mandatory requirement to post results
of registered trials would improve completeness and
transparency in reporting [8]. Once posted, it would be
impossible to conceal negative or null findings. Theoretic-
ally, removing this reason for not publishing would pos-
sibly, among other factors, increase trial publication rates.
The Food and Drug Administration Amendments Act of
2007 (FDAAA) [28] paved way for mandatory (specified
group of trials) as well as voluntary posting of results to a
results database that was added to the ClinicalTrials.gov
registry in 2008. Although there are some contradictory
reports [29], both trial registration and mandatory results
reporting have been shown to improve publication rates
[30–32].
Studies have previously assessed delayed or incomplete
publication in several specialties (including cancer trials
in general) [11, 12, 33, 34], with some assessing the
influence of the introduction of the ClinicalTrials.gov
results database on publication rates [29, 30, 32]. A
search of the literature failed to identify reports related
to this issue in relation to breast cancer trials. Consider-
ing that breast cancer is one of the leading causes of
morbidity and mortality in the world today [35, 36], this
study sought to (1) determine the proportion of regis-
tered breast cancer trials (i.e. initiated after February
2000) completed/terminated on or before 31 July 2013
that were published in peer-reviewed journals overall
and within 24 months of completion; (2) compare publica-
tion rates for trials completed before introduction of a
results database (from initiation of the database in February
2000 to 31 September 2008) with those completed
afterwards (from 1 October 2008 to 31 July 2013); and
(3) outline the main trial characteristics associated with
results’ publication. ClinicalTrials.gov was used becausenot only is it the largest publicly available registry
(195,624 registered trials as of 30 July 2015) but it also
combines the registry with a results database [8, 37].
Methods
Study design
This was a cross-sectional study of breast cancer trials
registered at ClinicalTrials.gov.
Search strategy
ClinicalTrials.gov was searched on 1 August 2015 by
browsing through the different conditions by category/
topic. Under the category ‘Cancers and Other Neoplasms’,
the two subcategories ‘Breast Neoplasms’ and ‘Breast
Neoplasms, Male,’ were chosen and the registry contents
downloaded.
Selection of relevant trials
Inclusion criteria
Both experimental and observational trials under the
subcategories ‘Breast Neoplasms’ and ‘Breast Neo-
plasms, Male,’ with primary completion or termination
dates up to 31 July 2013 were included (this was to
allow for a 24 month period; 1 August 2013 to 31 July
2015). The primary completion date was defined as the
date of collection of the primary outcome measure for
the last included patient [38] (when unreported, the ex-
pected completion date as defined by the trial investiga-
tors was used); whereas termination date as a premature/
early date on which participant recruitment, examination
and, or treatment stops with the trial not scheduled to
start again [38].
Exclusion criteria
‘Ongoing’ trials, trials initiated before/during February
2000, trials completed after 31 July 2013, terminated
trials that did not enrol a single participant and trials
with ‘unknown’ status or unknown completion dates
were excluded. ‘Ongoing’ trials were defined as trials
that were ‘active, but not recruiting’, ‘suspended’, ‘enrolling
by invitation’, ‘recruiting’, ‘not yet recruiting’, ‘available for
expanded access’ and ‘temporarily not available for ex-
panded access’, whereas trials with ‘unknown status’ were
those trials whose recruitment status had not been verified
within the previous two years for ‘recruiting’ or ‘not yet
recruiting’ studies [38]. A track of trials included per study
period was kept with trials in a given period excluded once
an accumulated number of 170 trials in the same period
was reached.
Size of selected sample
This was based on the ‘sample size calculation formula
for a difference in proportions’ [39]. Using the Ramsey
and Scoggins [33] publication rate of p1 = 17.6 % (before
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suming a type I error rate of 5 %, power calculations
were undertaken under various publication rate incre-
ments including 10 % (724 trials), 15 % (340 trials) and
20 % (199 trials). The 15 % absolute change in publica-
tion rate (i.e. p2 = 32.6 %), which produced 340 trials in
total or 170 trials per study period, was decided on since
it reflected a reasonably large increment whilst still re-
quiring a manageable sample size.
Sampling technique
A web-based random number generator [40] was used
to generate a sequence of random numbers from within
the range of 1 to 6389, 6389 being the number of breast
cancer trials registered with ClinicalTrials.gov as of 1
August 2015 (Table 1). Using the generated sequence,
the first 170 trials from each trial period fulfilling inclu-
sion/exclusion criteria (below) were selected.
Data extraction
A Microsoft Office Excel template was used to extract
information from downloaded content including trial
characteristics (design: type, phase, randomization sta-
tus, control status, blinding, interventional model, and
endpoint classification; population: age and gender;
sample size; study location; registration before/after ini-
tiation; and, primary sponsor); completion/termination
status (completed or terminated, month and year of com-
pletion/termination, completed before/after 1 October
2008 and registered before/after completion/termination);
results’ posting in ClinicalTrials.gov (results posted or
not; time to posting results); and trial publication status
(results published or not, journal of publication, and
time to publication).
Search for corresponding publications
For the literature search of published trials, the publi-
cation link (or citation) within the ClinicalTrials.gov, if
available, was used. If no link (or citation) was avail-
able, a search was conducted in MEDLINE using the
ClinicalTrials.gov identification number (CTN). If no
publication was found using this number, another
search using the keywords ‘breast cancer’ and the study
intervention(s)’ primary outcomes and/or principal inves-
tigator (if named) was conducted. Articles were matchedTable 1 Breast cancer trials registered with ClinicalTrials.org as
of 1 August 2015
Breast cancer category
(number of trials)
ClinicalTrials.org number
(study rank)
Allocated survey
number
Breast Neoplasms
(6109 studies)
1–6109 1–6109
Breast Neoplasms,
Male (280 studies)
1–280 6110–6389to the registry information using the study description,
primary and secondary objectives, location, enrolment
start and end dates, etc. For multiple publications, the
publications that most closely fitted the study descrip-
tion in the registry records were chosen. If a decision
could not be made on this basis (i.e. for two or more
publications both/all closely fitting the registry records)
or, if the same publication was published twice, the
earliest publication (including electronic publications)
was used. For studies whose publication records were not
found using the MEDLINE search, a similar search was
conducted using University of Liverpool’s DISCOVER.
DISCOVER is the University of Liverpool’s electronic li-
brary database which contains/links to sources from
more than 489 other databases including MEDLINE,
Scopus, Science Citation Index, Science Direct, CINAHL
Plus, Cochrane database of systematic reviews, EBSCO,
ProQuest, Bandolier, etc. [41]) The search included
publications for all languages with non-English publica-
tions included if a translated abstract and/or main text
was available. For published trials, the journal and date
of publication, the database in which published records
were found and the study’s visibility using a CTN search
as well as the reporting of the CTN in the title/abstract
were captured. Unpublished studies that had meeting
abstracts were also documented but not included as full
publications.
From both the ClinicalTrials.gov and publication re-
cords, other measures were derived including registered
before/after initiation/completion, registered within
21 days if not prospectively registered, time in months
from receipt of certification or request for extension to
delay results, time in months from completion to publi-
cation/posting in ClinicalTrials.org and whether or not
results were posted 12 (or published 24) months or
less. Finally and depending on the year of publication,
each journals’ impact factor was obtained by viewing
the respective ‘Journal Citation Reports’ available from
the ISI Web of Science. Data collection was completed
on 31 August 2015.
Data cleaning
This involved the review of trial registries to check for and
rectify typographical errors. Missing/unclear/inconsistent
data variables were resolved as shown below (completion
dates were not altered since they had been used to classify
the registry records into the two study periods):
 Some missing data was resolved (imputed) by using
other ClinicalTrials.gov information. For instance,
since all single-group assignments/designs are non-
randomized, open-label and have no control group
[38], all studies that had missing information under
‘randomization status’, ‘blinding status’ and/or
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were labelled ‘single-group assignment’. For those
that had inconsistent data, e.g. a ‘single-group as-
signment’ also labelled as ‘placebo-controlled,’ the
study’s description in the narrative text, if available,
and/or the study’s objectives were used to resolve
the issue. Similarly, the study’s objectives were used
to impute missing ‘endpoint classifications’ whereas
studies with more than one listed site or conducted
in more than one country had to be ‘multicentre’.
 For studies with publications, unresolved missing/
inconsistent data was imputed using information
from published records. For inconsistencies between
registry and published records. e.g. achieved sample
size, published records took precedence.
 For information especially age ranges that did not
perfectly match the data categories as per the data
extraction template, the closest category was recorded,
e.g. a study recruiting participants ≥21 years but
<70 years was considered to be in the ‘Adults
(≥18 years, <65 years) only’ category.
Finally, to aid data analysis, all missing/blank fields
were completed using a ‘0’ except for those fields that
required ‘time to completion, in months’ (in relation to
results posting within ClinicalTrials.gov and publication
in peer-reviewed journals), ‘sample size’ and ‘number of
multiple centres’.
Analysis
The IBM Statistical Package for Social Sciences (SPSS)
Version 21 was used. Descriptive analysis was used to
identify the main trial characteristics as well as the pro-
portions of the main outcome measures. Associations be-
tween selected variables were examined using chi-square
tests (both variables categorical), independent sample T
test/Mann-Whitney/logistic regression (one categorical,
one quantitative) or linear regression (both quantitative).
Conducted tests included:
 Tests between the two study periods versus the trial
characteristics to ascertain whether/not trial
characteristics were different across the two periods
 Tests between the two study periods versus
publication status (published/not within 24 months
and time to publication) to compare publication
rates and timeliness across the two periods
 Tests between publication status (results published/
not) versus trial characteristics to determine which
trial characteristics were associated with trial
publication
The Kaplan-Meier survival method was used to com-
pare the cumulative probability of trials being publishedwithin 24 months for the two study periods (all trials
without publications after a 24-month follow-up were
censored). Finally, all factors that were associated to
publication status (p value ≤.25) [42] were introduced in
a multivariate logistic regression to identify factors inde-
pendently associated with publication status. To examine
the effects of multiple testing, the Bonferroni adjustment
method [43] was employed.
Results
Trial selection and characteristics
A total of 340 registered trials were included as shown
in Fig. 1 (also see Additional file 1). The majority of
these trials were interventional, phase I/II or II, non-
randomized, had no control, open-label, of single-group
assignment and assessed both safety and efficacy
(Table 2). The median sample size was 48 (first quartile,
Q1 = 24, third quartile, Q3 = 118) with most trials includ-
ing female participants aged ≥18 years old. Most trials
were multicentre; and, of the multicentre trials that re-
ported the number of centres (n = 87), the median number
of sites was 9 (Q1 = 4, Q3 = 23). The primary sponsor was
categorized as non-industry/non-government in 60.9 % of
the trials. The registration, completion/termination and
results posting statuses of the same trials are also pre-
sented in Table 2. A notable observation is that most
(70.9 %) trials were not prospectively registered (i.e. before
initiation). When registration within 21 days of initiation
was considered, an extra 34 trials were registered ad-
equately. The median year or trial completion was 2008
(Q1 = 2007, Q3 = 2011). Only 59 (17.4 %) trials had posted
results with a median time to posting results of 24 months
(Q1 = 13 months, Q3 = 49 months) (of these, only 14 had
posted results within the required 12 months). For trials
without posted results, only 7 had applied for a certifica-
tion or request for extension to delay results. However,
these trials had not posted results even after a median
time of 31 months (from receipt of the certification/re-
quest by ClinicalTrials.gov). The greatest proportions of
unknown/missing values were recorded in the categories
‘number of centres’ and ‘number of centres, if multiple’
which respectively had 37.1 and 47.0 % values missing.
A comparison of trial characteristics between the two
study periods for continuous variables using the Mann-
Whitney U test, i.e. sample size (N = 340, U = 14,447.0,
Sig. =.997), number of multiple centres (N = 87, U =
915.0, Sig. =.857) and time to posting of results (N = 59,
U = 237.5, Sig. =.014) showed that only the latter was
statistically significantly different across the periods.
Other comparisons are shown in Table 2. Overall, 8/22
factors/characteristics differed between the two periods
including trial type, blinding status, number of centres
(single versus multiple), registration before trial initiation,
registration within 21 days of trial initiation, registration
Fig. 1 Selection of trials
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(including time to posting) in ClinicalTrials.gov.
Overall publication of study results
Of the included trials (n = 340), only 77 had valid publi-
cation links. The links (n = 77) and a MEDLINE search
using the ‘ClinicalTrials.gov identifier (CTN)’ (n = 5)
and ‘applicable search terms’ (n = 86) produced a total
of 168 trials (Additional file 2) published by MEDLINE-
indexed journals (with a median impact factor of 4.17,
Q1 = 2.63, Q3 = 6.41). Apart from 16 meeting abstracts
(excluded), the DISCOVER search did not yield any
more publications. Therefore, 49.4 % (168/340) of
breast cancer trials registered with ClinicalTrials.gov
were published, with a median time to publication of
24 months (Q1 = 14 months, Q3 = 42 months). The pub-
lication trend based on year of completion/termination
is shown in Fig. 2. Considering publication timeliness,
only 86 (51.2 %) of the 168 published trials (which
translates to 25.3 % of the 340 registered trials) were
published within 24 months of trial completion. With
regard to ‘visibility’, less than half (45.8 %, 77/168), a
third (27.4 %, 46/168) and a fifth (14.9 %, 25/168) of
published trials had publication links, were obtainable
using the CTN search and reported the CTN in the
title/abstract, respectively.Publication across the two study periods
Of the 168 trials published overall, 93 (55.4 %) trials
were completed/terminated before 1 October 2008
compared to 75 (44.6 %) that were completed/termi-
nated on/after 1 October 2008. Both trial periods had
an equal number of trials (n = 43, 25.3 % of 170 trials)
being published within 24 months. Chi-square tests did
not reveal an association between completion/termin-
ation before/after 1 October 2008 and results being
published within 24 months/not (OR = 1.00, 95 % CI
= .61 to 1.63, p value = 1.000, n = 340; OR adjusted for
type and completion/termination status = 0.84, 95 % CI
= .51 to 1.39, p value = .493, n = 340). Concerning time
to publication, Kaplan-Meier survival analysis (Fig. 3)
did not find a significant difference between the two
time periods (log rank test p value = .989).
Study characteristics associated with trial publication
The associations between publication status (results
published/not) with trial characteristics (Table 2) re-
vealed that observational studies were less likely to be
published than interventional studies (OR = .23, 95 % CI
= .11 to .50, p value < .0001, n = 340) whereas terminated
trials were less likely to be published than those com-
pleted as planned (OR = .29, 95 % CI = .15 to .56, p value
<.0001, n = 340). There was also a significant difference in
Table 2 Trial characteristics, comparison between the two study periods and publication status.
Trial characteristics Frequencyc Completion/terminationc p valuea Publication Statusd p valuea
Before 1
Oct 2008
On/after 1
Oct 2008
Published Not Published
Type Interventional 297 (87 %) 158 (93 %) 139 (82 %) .002 159 (54 %) 138 (47 %) <.0001
Observational 43(13 %) 12 (7 %) 31 (18 %) 9 (21 %) 34 (79 %)
Phase I 47 (14 %) 28 (21 %) 19 (17 %) .917b 21 (45 %) 26 (55 %) .161b
I/II or II 145 (43 %) 80 (59 %) 65 (60 %) 85 (59 %) 60 (41 %)
II/III or III 45 (13 %) 24 (18 %) 21 (19 %) 29 (64 %) 16 (36 %)
IV 8 (2 %) 4 (3 %) 4 (4 %) 6 (75 %) 2 (25 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 52 (15 %)
Randomization status Randomized 107 (32 %) 60 (39 %) 47 (34 %) .409 63 (59 %) 44 (41 %) .229
Non-randomized 186 (55 %) 95 (61 %) 91 (66 %) 96 (52 %) 90 (48 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 4 (1 %)
Control status Placebo only 29 (9 %) 16 (10 %) 13 (10 %) .136b 15 (52 %) 14 (48 %) .519b
Active-control only 74 (22 %) 34 (22 %) 40 (29 %) 41 (55 %) 33 (45 %)
Both placebo and active-
control
17 (5 %) 13 (8 %) 4 (3 %) 12 (71 %) 5 (29 %)
No control 172 (51 %) 92 (59 %) 80 (58 %) 90 (52 %) 82 (48 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 5 (2 %)
Blinding Open-label 255 (75 %) 128 (82 %) 127 (93 %) .006b 134 (53 %) 121 (48 %) .286b
Single-blind 9 (3 %) 5 (3 %) 4 (3 %) 4 (44 %) 5 (56 %)
Double (or Triple) blind 30 (9 %) 24 (15 %) 6 (4 %) 20 (67 %) 10 (33 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 3 (1 %)
Interventional model Parallel 107 (32 %) 54 (35 %) 53 (39 %) .432b 60 (56 %) 47 (44 %) .184b
Crossover 9 (3 %) 7 (5 %) 2 (2 %) 4 (44 %) 5 (56 %)
Factorial 4 (1 %) 2 (1 %) 2 (2 %) 4 (100 %) 0 (0 %)
Single-group assignment 172 (51 %) 92 (59 %) 80 (58 %) 90 (52 %) 82 (48 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 5 (2 %)
Endpoint classification Safety only 28 (8 %) 15 (10 %) 13 (10 %) .336b 12 (43 %) 16 (57 %) .069b
Efficacy only 103 (30 %) 49 (32 %) 54 (40 %) 49 (48 %) 54 (52 %)
Both Safety and Efficacy 160 (47 %) 91 (59 %) 69 (51 %) 96 (60 %) 64 (40 %)
Not applicable
(observational studies)
43 (13 %)
Unknown (missing values) 6 (2 %)
Age Included adults (≥18 years,
>65 years)
51 (15 %) 28 (18 %) 23 (15 %) .697b 29 (57 %) 22 (43 %) .716b
Included adults and older
adults (≥65 years)
237 (70 %) 121 (76 %) 116 (75 %) 117 (49 %) 120 (51 %)
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Table 2 Trial characteristics, comparison between the two study periods and publication status. (Continued)
Included adults and children
(<18 years)
5 (2 %) 2 (1 %) 3 (2 %) 2 (40 %) 3 (60 %)
Included older adults
(≥65 years) only
20 (6 %) 8 (5 %) 12 (8 %) 9 (45 %) 11 (55 %)
Included children
(<18 years) only
0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
Unknown (missing values) 27 (8 %)
Gender Male only 1 (0 %) 0 (0 %) 1 (1 %) .136b 0 (0 %) 1 (100 %) .132b
Female only 225 (66 %) 106 (62 %) 119 (70 %) 105 (47 %) 120 (53 %)
Both male and female 114 (34 %) 64 (38 %) 50 (29 %) 63 (55 %) 51 (45 %)
Number of Centres Single 50 (15 %) 18 (17 %) 32 (29 %) .035 34 (68 %) 16 (32 %) 1.000
Multiple 164 (48 %) 87 (83 %) 77 (71 %) 112 (68 %) 52 (32 %)
Unknown (missing values) 126 (37 %)
Number of Countries Single 301 (89 %) 148 (88 %) 153 (91 %) .469 143 (48 %) 158 (53 %) .013
Multiple 36 (11 %) 20 (12 %) 16 (10 %) 25 (69 %) 11 (31 %)
Unknown (missing values) 3 (1 %)
Country US/Canada only 209 (62 %) 105 (63 %) 104 (62 %) .855b 100 (48 %) 109 (52 %) .013b
International (outside USA/
Canada) only
102 (30 %) 49 (29 %) 53 (31 %) 48 (47 %) 54 (53 %)
USA/Canada and
International
26 (8 %) 14 (8 %) 12 (7 %) 20 (77 %) 6 (23 %)
Unknown (missing values) 3 (1 %)
Primary sponsor Industry 91 (27 %) 45 (27 %) 46 (27 %) .609 45 (50 %) 46 (51 %) .545b
Government (US and non-US) 42 (12 %) 24 (14 %) 18 (11 %) 24 (57 %) 18 (43 %)
Non-industry/non-
government
207 (61 %) 101 (59 %) 106 (62 %) 99 (48 %) 108 (52 %)
Registered before initiation Yes 59 (17 %) 22 (14 %) 37 (27 %) .005 35 (59 %) 24 (41 %) .171
No 241 (71 %) 139 (86 %) 102 (73 %) 119 (49 %) 122 (51 %)
Unknown (missing dates) 40 (12 %)
Registered within 21 days
of initiation
Yes 93 (27 %) 30 (19 %) 63 (30 %) .000 47 (51 %) 46 (50 %) .980
No 217 (64 %) 127 (81 %) 90 (59 %) 110 (51 %) 107 (49 %)
Unknown (missing dates) 30 (9 %)
Completed/terminated Completed 288 (85 %) 148 (87 %) 140 (82 %) .228 155 (54 %) 133 (46 %) <.0001
Terminated 52 (15 %) 22 (13 %) 30 (18 %) 13 (25 %) 39 (75 %)
Registered before
completion/termination?
Yes 283 (84 %) 131 (78 %) 152 (90 %) .002 135 (48 %) 148 (52 %) .155
No 55 (16 %) 38 (23 %) 17 (10 %) 32 (58 %) 23 (42 %)
Unknown (missing dates) 2 (1 %)
Results posted in
ClinicalTrials.gov?
Yes 59 (17 %) 20 (12 %) 39 (23 %) .007 31 (53 %) 28 (48 %) .597
No 281 (83 %) 150 (88 %) 131 (77 %) 137 (49 %) 144 (51 %)
Publication link available Yes 77 (23 %) 41 (24 %) 36 (21 %) .517 77 (100 %) 0 (0 %) <.0001
No 263 (77 %) 129 (76 %) 134 (79 %) 91 (35 %) 172 (51 %)
aPearson chi-square p values used unless otherwise. For cells with expected cell count less than 5, exact p values (Fisher’s exact test or Monte Carlo significance)
were used
bLikelihood ratio p value
cPercentages by column for frequencies and study period comparisons (some percentages may not add up to 100 % due to rounding)
dPercentages by row for publication comparisons
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tries and those conducted in multiple countries (OR = .40,
95 % CI = .19 to .84, p value = .013, n = 337). Finally, thecountry of location was significantly associated with publi-
cation status (p value = .013). Although the availability of a
publication link is shown in Table 2 (p value < .0001), the
Fig. 2 Publication (number of trials) by year of completion/termination
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posing factor to publication because of a clear temporal
relationship (publication precedes establishment of a link).
None of the continuous variables was significantly associ-
ated with publication status (Mann-Whitney U tests were
sample size, N = 340, U = 12716.0, Sig. =.056; number of
multiple centres, N = 87, U = 275.5, Sig. =.944; and time to
posting of results, N = 59, U = 407.5, Sig. =.687 whereas
logistic regression ORs (95 % CIs) were sample size, OR =
1.00, 95 % CI = 1.00 to 1.00; number of multiple centres,
OR = .98, 95 % CI = .94 to 1.03; and time to posting of re-
sults, OR = 1.00, 95 % CI = .98 to 1.02).
Chi-square comparisons between early phase (phase I
and I/II or II) versus late phase (phase II/III or III and IV),
blinded (single, double or triple blind) versus not-blinded
(open-label) and industry versus non-industry funding
with regard to results publication were also compared.
The results (together with associations of other dichotom-
ous trial characteristics) are presented in Fig. 4.
On multivariate analysis, only trial type (observa-
tional versus interventional studies) (adjusted OR = .28,
95 % CI = .10 to .74) and completion/termination status
(terminated versus completed as planned) (adjusted ORFig. 3 A comparison of the cumulative probability of trials being
published over time across the two study periods (all trials followed
up for 24 months)= .22, 95 % CI = .09 to .51) were associated with publica-
tion status.Examination of the effects of multiple testing
A total of 45 tests (21 comparing trial characteristics across
the study periods, 2 between the study periods and publi-
cation status and 22 examining trial characteristics associ-
ated with publication status) were conducted. According to
Bland [43], these many tests inflate the α (type I) error.
For the overall study error to remain at the set α level, the
Bonferroni adjustment sets a new error rate of 1 − (1 − α)n
(which approximates α/n), where n is the number of tests
performed. 0.05/45 = .001. Using this p value, only two
associations (results published/not with trial type and
results published/not with completion/termination status)
remained significant.Discussion
Principal findings
This study was designed to measure the publication
proportion for registered breast cancer trials and detect
any changes in the same after the 2008 introduction of
the ClinicalTrials.gov results database. First and foremost,
the proportion of trials published within 24 months was
very low at 25.3 % (increasing to 49.4 % when publication
timeliness is not considered). Although these figures
are higher than those earlier reported (for oncology
trials) [11, 33], a majority of registered trials remain
unpublished, which is worrisome given that oncology
was among the first medical fields to widely adopt trial
registration [44]. Overall, more trials were published in
the period prior to compared to that after 1 October
2008 (55.4 versus 44.6 %). However, it is not possible to
associate this difference to the introduction of the re-
sults database since trials conducted before 1 October
2008 had a longer follow-up [45]. Indeed, this difference
Fig. 4 Non-adjusted ORs (95 % CIs) of results publication for selected trial (dichotomous) characteristics
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same 24-month period (50 versus 50 %).
For both study periods, a majority of studies remained
unpublished. This study however did not evaluate the
reasons such studies were not published. Reasons for non-
publication of research studies have nevertheless been
discussed elsewhere [7, 11, 33, 45–48]. It is, however, also
possible that some studies designated as ‘unpublished’
were still undergoing preparation for publication or edi-
torial review and will soon be published [49, 50]. This is
especially important since the study’s minimum follow-up
period was 2 years yet according to Hopewell et al. [50],
positive and negative findings are on average published
within 4–5 and 6–8 years respectively. Schmucker and
colleagues also noted that the probability of publication
within 2 years, for their study, ranged from 7 to 30 % [51].
As Manzoli [52] demonstrated publication rates increase
with time, with a follow-up of 355 vaccine trials showing
publication rates of 12, 29, 53 and 73 % after 12, 24, 36
and 48 months after completion, respectively. For this
study therefore, trials completed before 1 October 2008
with a minimum follow-up of 7 years should have had
enough time for publication. Worryingly, 45.3 % (77/170)
of these trials were not published which is in line withKhan et al.’s [15] report that 20 to 70 % of trials remain
unpublished even after a follow-up of several years.
Only trial type (interventional versus observational)
and completion/termination status were associated with
trial publications. As mentioned earlier, registration of
trials was introduced among other reasons to ensure the
complete reporting of the same trials [8]. With FDAAA
[28] among other laws not mandating their registration,
exacerbated by the fact that the medical community has
given them little attention with regard to their need to
be registered [53], it is no surprise that the publication
proportion of observational trials was much less than
that of interventional trials. However as Williams and
colleagues [53] explain, most, if not all, ethical and sci-
entific reasons that prompted registration of interven-
tional studies also apply to observational studies. They
should therefore also be registered (and results publicly
disseminated). With regard to completion/termination
status, reasons similar/related to those for termination
(e.g. recruitment failure, safety concerns, futility, eco-
nomic reasons, etc.) [31, 54] may discourage those initi-
ating/conducting/funding the same trials from investing
more time/money into their publication. However, as
Shamliyan and Kane [31] report, reporting of such trials
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concerns. Lessons learnt from such trials are important
in shaping future research [3].
Study strengths and weaknesses
To the best of the researchers’ knowledge, this is the first
study to determine publication rates in the breast cancer
field and compare such rates before and after the
introduction of the ClinicalTrials.gov results database.
ClinicalTrials.gov is currently the largest registry/results
database which contains trials conducted from almost all
areas of the world. It is also publicly available meaning
any researcher can access and replicate the study if scien-
tifically/ethically justifiable. By allowing a 2-year period,
the study ensured that completed/terminated trials had at
least 2 years to be published in peer-reviewed journals.
However, several limitations are recognized.
 First, the study was designed to detect a 15 %
change in publication rate yet the observed change
was 10.6 % (54.7 to 44.1 %). A difference of 10 %
required a sample size of 724 trials. The study’s
smaller sample size produced less precise results
(wider CIs) which could have affected the statistical
significance of some of the associations as well as
their interpretation [42].
 Secondly, although ClinicalTrials.gov is the largest
publicly available database, the majority of trials
originate from the USA/Canada (Table 2) which
as Herrmann et al. [55] note might limit
generalizability of the findings.
 Thirdly, the study relied on the accuracy of
information in the ClinicalTrials.gov registry.
However, this has previously been found to be
unreliable [52, 56]. Incomplete, inconsistent or
inaccurate records (e.g. some included studies were
published before their registered completion dates)
negatively impact the validity of the study’s findings.
For instance, as Ross et al. report, studies providing
completion dates are generally more likely to be
published than those not providing the same dates
[7]. This implies that this study, by not including
studies without completion dates, may have
overestimated the proportion of published studies in
the registry. Additionally, because studies did not
provide the date/day of completion, the time to
publication (months) was approximate. Where it
was possible to rectify inconsistencies/inaccurate/
incomplete information, this was done as described
under the ‘Data cleaning’ section.
 Fourthly, although the Bonferroni adjustment was
used to assess the effects of multiple testing, it was
not employed to adjust for the type I error. The
Bonferroni adjustment discourages multiple tests yetthese are necessary for the interpretation of findings;
it also increases the type II error (‘false negatives’)
[57]. As Perneger [57] summarizes, “…simply
describing what tests of significance have been
performed, and why, is generally the best way of
dealing with multiple comparisons.” The number
of tests conducted (and why) were described in
the analysis section. It should be noted that the
‘primary’ outcome (proportion of published trials)
which was in the first instance not significant
would not be affected by any Bonferroni adjustment.
The only affected tests were ‘secondary’ (i.e. used to
interpret the ‘primary’ finding) and were therefore of
less relevance to the overall effect of multiple testing
on the study’s results.
 Fifthly, the study design did not include the
assessment of unpublished findings. Nevertheless,
the registry does not contain contact information
for completed trials (contains only for ‘recruiting’
or ‘not yet recruiting’ trials) [58] which would have
made it difficult had the researcher opted to
contact investigators to assess unpublished findings.
 Sixthly, it is possible that the study missed some
published reports. However, as Manzoli states, any
publications missed using the study’s systematic
search are in essence not ‘publicly available’ or
‘visible’ to the public and are unlikely to be identified
during subsequent/routine searches [52].
 Finally, a single researcher derived information
from the ClinicalTrials.gov registry in addition to
searching for publication records. The lack of a
second independent search/data extraction lessens
scientific vigour since it is impossible to rectify
(and/or quantify) issues identifiable thorough
researcher disagreements [49].
Policy implications
This study has several implications. First, the lack of
publications or delays in publishing trial results means
that at any one time, available evidence will be incom-
plete [2–10, 59]. Incomplete evidence in turn affects
most, if not all, populations including researchers
(conducting systematic reviews or further research that
needs to be guided by current evidence), health service
providers (making treatment decisions), policy makers
(making treatment guidelines), patients with their friends
and families (final healthcare consumers) and healthcare
funders who pay for the treatment interventions.
Wrong policy decisions, treatments given or research
conducted is wasteful of limited resources. Secondly,
patients, healthcare providers, funders, ethical boards,
etc. participate in/fund or approve research with the
hope that results will be disseminated and used to inform
clinical practice. A failure to publish research findings
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unethical but could be regarded as scientific misconduct.
In the long run, it erodes the public trust in clinical re-
search [2–10, 59]. It is hoped that all concerned (including
but not limited to researchers, journal editors, peer re-
viewers, sponsors, policymakers, regulators, Institutional
Review Boards or Research Ethics Committees, etc.) will
continue to work toward the attainment of complete and
transparent reporting in the breast cancer and other fields
(the OPEN (Overcome failure to Publish nEgative fiNd-
ings)) project has developed targeted recommendations to
that effect [60]) so that ultimately patients, healthcare pro-
fessionals, funders, researchers, etc. benefit through eth-
ical, scientific and efficient utilization and advancement of
medical knowledge.
Conclusions
Less than a half of breast cancer trials registered in
ClinicalTrials.gov are published in peer-reviewed jour-
nals. Although this is an overall improvement from
earlier reported oncology trials [11, 33], the results of
the findings suggests the results of the majority of
breast cancer trials remain unavailable to the public.
These findings raise both ethical and scientific concerns
and question both the completeness and validity of the
evidence base that guides treatment decisions/guidelines,
further research among others with regard to breast can-
cer treatments. Additionally, they question the effective-
ness of the measures including registries and results
databases (or their implementation) that have over time
been introduced to limit selective, incomplete and delayed
publication.
Recommendations
As Zarin and Tse explain with regard to trial registration,
“…the infrastructure…is in place, but culture change by
all stakeholders…is necessary before key goals can be
reached.” [61] It is important therefore that this ‘cultural
change’ be facilitated and the existing infrastructure
strengthened. This among others includes increasing the
capability of ClinicalTrials.gov to detect and enable rectifi-
cation of incomplete, inaccurate or inconsistent entries
(especially applicable optional data elements) (see Table 2
for proportions of incomplete entries). Responsible au-
thorities should be made accountable for complete, accur-
ate and up-to-date information. ClinicalTrials.gov should
retain contact information for completed (especially un-
published) trials. The trial registry should also include a
field that enables viewers determine whether/not a study
is required to post results as mandated by FDAAA. There
should be enforcements (rewards and punishments) at all
levels; e.g. Institutional Review Boards, peer reviewers or
journal editors should not respectively approve, approve
for publication or publish (unless otherwise/justifiable)applicable trials that are not prospectively registered, do
not have trial registration numbers or have not posted re-
sults as required by the FDAAA (many published trials
did not fulfil these requirements).
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